


## Dilantha Perera (Autor)

## A toolkit to study nuclear transport pathways: nanobody-mediated inhibition of importin β-related nuclear transport receptors (NTRs)



https://cuvillier.de/de/shop/publications/8870

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany

Telefon: +49 (0)551 54724-0, E-Mail: info@cuvillier.de, Website: https://cuvillier.de

## **Table of Contents**

Thesis Committee and Examination Board Members	i
Epigraph	ii
List of Figures	vi
List of Tables	viii
Summary	1
1 Introduction	2
1.1 Compartmentalization of eukaryotic cells	2
1.2 Nuclear pore complex 1.2.1 Architecture of the NPC	<b>2</b> 3
<ul><li>1.3 Permeability barrier of the NPC</li><li>1.3.1 FG repeat domains and FG-Nups</li><li>1.3.2 Models of NPC Transport selectivity</li></ul>	<b>3</b> 4 5
<ul> <li>1.4 Nuclear transport receptors</li> <li>1.4.1 Characteristics of Importin β-like NTRs</li> <li>1.4.2 RanGTP gradient and NTR transport directionality</li> <li>1.4.3 RanGTP interaction with Importin β-like NTRs</li> <li>1.4.4 Nuclear transport pathways</li> <li>1.4.5 NTR cargo recognition</li> </ul>	<b>7</b> 7 8 10 11 13
1.5 Overview of selected NTRs 1.5.1 Transportin 1 1.5.2 Exportin 4 and Exportin 7 1.5.3 CAS	<b>14</b> 14 16 18
1.6 Tools to investigate NTR mediated transport pathways 1.6.1 Genetic perturbations 1.6.2 Targeted protein degradation 1.6.3 NTR inhibition using small molecules 1.6.4 Nanobodies to investigate NTR pathways	20 20 21 21 22
<ul><li>1.7 Nanobodies</li><li>1.7.1 Nanobody library generation</li><li>1.7.2 Nanobody selection: phage display</li></ul>	<b>22</b> 23 24
1.8 Aim of this study	26
2 Results	27
2.1 Biochemical characterization of anti-NTR nanobodies 2.1.1 Nanobodies selected against TRN1 2.1.2 Nanobodies selected against Xpo7 2.1.3 Nanobodies selected against Xpo4	27 28 31 34

2.1.4 Nanobodies selected against CAS	37
<b>2.2</b> <i>In vivo</i> validation of Nb-mediated NTR pathway inhibition 2.2.1 Inhibition of the TRN1 pathway in HeLa cells 2.2.2 Inhibition of the CAS pathway in HeLa cells	<b>39</b> 39 40
<ul> <li>2.3 Inhibition of NTR-facilitated transport through NPCs in permeab cells</li> <li>2.3.1 Nb-meditated inhibition of TRN1</li> <li>2.3.2 Nb-meditated inhibition of Xpo7</li> <li>2.3.3 Nb-meditated inhibition of Xpo4</li> <li>2.3.4 Nb-meditated inhibition of CAS</li> </ul>	43 43 46 48 51
2.4 Tag-Nbs to interrupt NTR-facilitated transport through NPCs in permeabilized cells 2.4.1 Inhibition of TRN1 2.4.2 Inhibition of Xpo7 2.4.3 Inhibition of Xpo4 2.4.4 Inhibition of CAS	<b>55</b> 55 58 61 64
<ul> <li>2.5 Impeding NTR-facilitated transport into reconstituted FG hydrog</li> <li>2.5.1 Impeding TRN1-facilitated partitioning into FG particles</li> <li>2.5.2 Impeding Xpo7-facilitated partitioning into FG particles</li> <li>2.5.3 Impeding Xpo4-facilitated partitioning into FG particles</li> <li>2.5.4 Impeding CAS-facilitated partitioning into FG particles</li> <li>2.5.5 Orthogonal tag-Nbs to impede NTR-facilitated partitioning into FG particles</li> </ul>	68 70 71 72
3 Discussion	76
3.1 Functional classification of the selected anti-NTR Nbs 3.1.1 Semi-inhibitory nanobodies 3.1.2 Mildly inhibitory Nbs 3.1.3 NTR blockers: red lights on the NTR pathway	<b>76</b> 76 78 79
3.2 Tag-Nbs: the good, the bad, and the redundant 3.2.1 The benefits of tag-Nbs 3.2.2 Disadvantages and redundancies of tag-Nbs 3.2.3 Orthogonal tag-Nbs	<b>80</b> 80 82 84
3.3 Future Outlook 3.3.1 Expanding and improving the toolkit 3.3.2 Studying the mechanics of Nb-NTR and FG-NTR interactions 3.3.3 Unravelling the NTR transport network	<b>85</b> 85 86 86
4 Materials and Methods	88
4.1 Chemicals, proteins, and reagents	88
4.2 Molecular cloning 4.2.1 Design and validation 4.2.2 Polymerase chain reaction (PCR)	<b>88</b> 88

4.2.5 Transformation of bacteria 4.2.6 Plasmid DNA preparation	90 90
4.3 Protein purification 4.3.1 Recombinant protein expression 4.3.1 Recombinant expression of Nb constructs 4.3.2 Immobilized metal ion chromatography 4.3.3 Size exclusion chromatography 4.3.4 SDS-PAGE 4.3.5 Protein labeling using maleimide chemistry	91 91 92 93 94 95
<ul><li>4.4 Binding assays</li><li>4.4.1 Pulldown assays</li><li>4.4.2 BioLayer Interferometry (BLI)</li></ul>	<b>96</b> 96 97
<ul><li>4.5 In vivo experiments</li><li>4.5.1 Cell culture</li><li>4.5.2 Transient transfection of HeLa cells</li><li>4.5.3 Confocal fluorescence microscopy</li></ul>	<b>98</b> 98 98 99
<ul><li>4.6 Permeabilized cell assays</li><li>4.6.1 Permeabilization of HeLa cells</li><li>4.6.2 Confocal fluorescence microscopy</li><li>4.6.3 Data analysis</li></ul>	<b>99</b> 99 100 101
<ul><li>4.7 Experiment using FG phase hydrogels</li><li>4.7.1 Expression and purification of Nup116 FG domains</li><li>4.7.2 FG particle assay</li><li>4.7.3 Confocal fluorescence microscopy</li><li>4.7.4 Data analysis</li></ul>	<b>101</b> 101 103 103
References	105
Acknowledgements	120
Curriculum vitae	121